Category: Legislative

The U.S. House voted this evening “to highlight the need to protect the integrity of the 340B program by halting pharmaceutical manufacturers’ unlawful actions that have resulted in overcharges to 340B covered entities.”

Reps. Abigail Spanberger (D-Va.) and David McKinley

The top Republicans on two U.S. House health subcommittees are leading a party effort to “craft legislative proposals that Republicans can advance after retaking the majority” in the November 2022 midterm elections. It is not known whether the group will

The U.S. House Appropriations Committee is pleased with the U.S. Health Resources and Services Administration (HRSA) for challenging six drug makers’ denials of 340B pricing when covered entities use contract pharmacies, the committee said in a report released yesterday. It encouraged

In addition to weighing in on the ongoing 340B contract pharmacy standoff (see related story), the U.S. House Appropriations Committee has entered the thicket of the highly controversial topics of 340B patient definition and provider eligibility.

In its report

Reps. David McKinley (R-WV) and Abigail Spanberger (D-VA) introduced the PROTECT 340B Act today, which would prohibit pharmacy benefit managers (PBMs) and other third-party payers from paying 340B providers below-market rates or engaging in other perceived discriminatory contracting practices. While

A congressman from New York asked U.S. Health and Human Services Xavier Becerra during a hearing yesterday if he will use his existing authority to protect hospitals from losing eligibility for 340B drug discounts due to changes in patient mix

U.S. Rep. Katie Porter (D-Calif.), a California Democrat with a significant national profile, yesterday introduced legislation to require drug manufacturers to pay a Medicare Part B rebate for certain drugs if the price of such drugs increases faster than inflation.